Author

K. Woroniecka

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:host-pathogen & immune response· 1 Organism:mouse· 1

Frequent Co-Authors

E. C. Lerner· 2 shared P. E. Fecci· 2 shared A. M. Hoyt-Miggelbrink· 1 shared A. Miggelbrink· 1 shared A. Mohan· 1 shared D. S. Wilkinson· 1 shared D. Wilkinson· 1 shared J. B. Finlay· 1 shared

Activity by Year

2023-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. C. Lerner

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Antigen presentation by tumor-associated macrophages drives tumor-infiltrating T cells from a progenitor exhaustion state to terminal exhaustion

J. Waibl Polania, A. M. Hoyt-Miggelbrink, W. H. Tomaszewski, L. P. Wachsmuth, S. J. Lorrey, D. S. Wilkinson, E. C. Lerner, K. Woroniecka, J. B. Finlay, K. Ayasoufi, P. E. Fecci

The paper identifies tumor-associated macrophages as key drivers of T cell exhaustion transition, showing their role in shifting progenitor exhausted T cells to terminal exhaustion and impacting immunotherapy response.

bioRxiv · Aug 11, 2023 · PreprintImmunology

A Novel MHC-Independent Mechanism of Tumor Cell Killing by CD8+ T Cells

E. C. Lerner, K. Woroniecka, V. D'Anniballe, D. Wilkinson, S. Lorrey, J. W. Polania, L. Wachsmuth, A. Miggelbrink, J. Raj, W. Tomaszewski, A. Mohan, X. Cui, M. Khasraw, M. D. Gunn, P. E. Fecci

This study shows CD8+ T cells can kill MHC-I-deficient tumor cells via NKG2D-NKG2DL interactions, independent of antigen recognition, and identifies this pathway as a potential therapeutic target.

bioRxiv · Feb 2, 2023 · PreprintImmunology